Abstract:Objective To detect the expression of CD 44V 6, VEGF and nm23-H1 genes and evaluate its clinical significances on ovarian cancerous tissue.Methods Monoclonal antibodies to CD 44V 6,VEGF,nm23-H1 and SABC immunohistochemistry method were used to detect the expression of CD 44V 6,VEGF and nm23-H1 on the tumor cell in 65 cases of human ovarian cancerous tissue,30 benign ovarian tumor and on the normal ovarian tissues.Results 1) The positive expression rates of both CD 44V 6 and VEGF in groups of ovarian cancers, of stages Ⅱ-Ⅳand of the patient’s survival below 5 years were respectively were higher than that in groups of benign tumors and normal ovarian controls,of stage Ⅰand of the patient’s survival above 5 years,P0.05.The expression rate of CD 44V 6 in metastatic lesions were higher than that in the primary tumor,but that of VEGF was not significant between them.2) The positive expression rate of nm23-H1 in groups of stage Ⅱ-Ⅳ,of the metastases and of the patient’s survival below 5 years were respectively lower than that in the groups of stage Ⅰ-Ⅱ,of primary lesions and of the patient’s survival above 5 years,P0.05.The expression rate of nm23-H1 gene in group of ovarian cancers was higher than that of benign tumor or normal controls too.3) No significant difference was abserved between groups of the patient’s age,of histological types of cancers,of pathological grades of the malignancy and sizes of residual focuses of cancer.Conclusions 1) The results in the experiment indicate that as the expression of CD 44 V6 and VEGF is higher in poor differentiated tmuor and when the diseases reach the lase stage,which is concordance with some documents in which CD 44V 6 is an agent promoting growth, infiltration and metastasis of tumor,and VEGF promote tumor’s vessel growth.2) The higher expression of nm23-H1 primary cancer than that on metastatic lesion in late stage also reflect the function of nm23-H1 as metastasis supressor gene. The result of higher expression of nm23-H1 in cancer group than that in benign tumors or normal controls may be considered as a host compensative phenomenon to suppress tumor.

The expressions and clinical significances of CD44 and CK18 in ovarian serous carcino-ma

Expression of Octamer-4 in Serous and Mucinous Ovarian Carcinoma.

Expression and clinical significance of P16, P15,and VEGF proteins in primary epithelial ovarian carcinoma

Immunostaining Study On The Expression Of Nf-Kappa B, Er, And Pr In Ovarian Serous Carcinoma

CD44s expression study in colorectal cancer tissues

Expressions of ABCG2 and CD44~+/CD24~- cells in breast carcinoma and their relationship with prognosis

Clinicopathological Characters and Prognostic Significance of Cytokeratins Expression in Intrahepatic Cholangiocarcinoma.

Expression of cytokeratin 7 and 20 in ovarian metastatic carcinomas

Expression of CD44V6,VEGF and nm23-H1 on Ovarian Cancerous Tissue and Its Clinical Significance

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors

Expression of CD44v6 and PCNA protein in colorectal carcinoma

Study of molecular markers in patients with endometrial carcinoma and its prognosis on the effectiveness

Expression of HER-2 and TOPO- Ⅱα in Ovarian Epithelial Cancer and Its Clinical Significance

Expression of BRCA2 in Ovarian Tumor Tissues and Its Clinical Significance

The Expression of P-gp,ToPo H Α,gst-Π and C-Erbb2 in Epithelial Ovarian Carcinoma and Its Significance

The Clinical Value of Serum CA125, HE4 and OPN in the Diagnosis of Ovarian Cancer

Expression and Prognostic Significance of CD44v6 in Primary Gastric Carcinoma

Expression and Significance of CD44 in Pancreatic Head Cancer

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer

Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125

[Profiling of serum tumor markers in patients with epithelial ovarian carcinoma]